Abstract | PURPOSE: METHODS: RESULTS: During the 5 years follow-up, the primary outcome occurred in 105 patients (18.4%) (71 had IS, 10 had TIA, 12 had MI, and 12 died). There were no significant differences in the primary outcome between clopidogrel group and aspirin group (16.5% vs. 20.3%) or between carriers of the CYP2C19 reduced-function alleles and noncarriers (21.8% vs.15.7%). In patients with aspirin therapy, CYP2C19 polymorphism was not associated with the primary outcome. However, in patients treated with clopidogrel, carriers of at least one CYP2C19 reduced-function allele had a 3-fold higher adjusted risk for primary outcome compared with noncarriers (95% confidence interval, 1.23 to 8.74). CONCLUSIONS: Among IS patients treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had a significantly higher rate of adverse vascular events than did noncarriers. It should avoid prescribing clopidogrel to these patients with known CYP2C19 polymorphisms.
|
Authors | Xingyang Yi, Jing Lin, Ju Zhou, Yanfeng Wang, Ruyue Huang, Chun Wang |
Journal | Oncotarget
(Oncotarget)
Vol. 9
Issue 25
Pg. 17725-17734
(Apr 03 2018)
ISSN: 1949-2553 [Electronic] United States |
PMID | 29707143
(Publication Type: Journal Article)
|